№ lp_1_2_41208
File format: docx
Character count: 2416
File size: 31 KB
Structured clinical referral source outlining eligibility criteria, required investigations, patient history, and MDT questions for the assessment of malignancy of unknown origin or cancer of unknown primary.
Document type:
Clinical referral form
Clinical area:
Oncology
Condition focus:
Malignancy of unknown origin; cancer of unknown primary
Healthcare system:
NHS
Target pathway:
MUO/CUP multidisciplinary team
Referral purpose:
MDT review and management planning
Required investigations:
CT CAP; imaging; biopsy or cytology
Exclusion criteria:
Site-specific cancers; haematological and non-epithelial malignancies; acute oncology emergencies
Performance assessment:
WHO performance status
Associated pathway:
MUO/CUP investigation and referral pathway
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2014
Region / city:
NHS
Topic:
Imaging, Radiology, Cancer Care
Document Type:
Audit
Author:
Dr Anu Anand, Dr Ann Anstee, R Balasubramaniam, M Szewczyk-Bieda
Target Audience:
Healthcare professionals, MDT coordinators, radiologists
Period of Action:
Ongoing
Approval Date:
Tuesday 16 September 2014
Last Review Date:
Sunday 26 September 2021
Descriptors:
Imaging, MDT meetings, radiology reports, cancer services, audit, compliance
Context:
This document outlines the standards and requirements for the availability of imaging and reports prior to MDT meetings, ensuring accurate and timely decisions regarding patient care.
Note:
Year
Year:
2023
Region / City:
United Kingdom
Topic:
Neuro-oncology, Brain Tumours
Document Type:
Referral Form
Organization / Institution:
Oxford University Hospitals NHS Foundation Trust
Author:
Daja Barton, Nicky Swadling
Target Audience:
Healthcare Professionals, Referring Consultants, MDT Members
Period of Validity:
Not specified
Approval Date:
August 2023
Date of Changes:
August 2023
Year:
2020
Region / City:
UK
Topic:
Urogynaecology
Document Type:
MDT proforma and pre-surgical checklist
Organization / Institution:
BSUG
Author:
Not specified
Target Audience:
Medical professionals in urogynaecology
Period of validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Note:
Date
CURRENT PERFORMANCE STATUS:
1-5:
0:
Asymptomatic: Fully active, able to carry on all pre-disease activities without restriction.
1:
Symptomatic but completely ambulatory: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.
2:
Symptomatic: <50% in bed during the day. Ambulatory and capable of all self-care but unable to carry out any work activities.
3:
Symptomatic: >50% in bed, but not bedbound. Capable of only limited self-care, confined to bed or chair 50% or more of waking hours.
4:
Bedbound: completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
5:
Death
BRAIN ANEURYSM:
MR ANGIOGRAM or CT ANGIOGRAM
BRAIN AVM/DAVF:
MR BRAIN or MR/CT ANGIOGRAM
SPINE AVM/DAVF:
MR SPINE
CAVERNOMA:
MR with T2 and/or susceptibility weighted/gradient echo sequences
FAMILIAL ANEURYSM SCREENING:
Imaging is NOT required or recommended before review.
INTRACRANIAL:
ANEURYSM, DAVF, VENOUS VARIX, INTRACRANIAL HAEMORRHAGE, SUBARACHNOID HAEMORRHAGE, CAVERNOMA
SPINAL:
AVM, DAVF, VENOUS VARIX, SPINAL HAEMORRHAGE, CAVERNOMA
Year:
2022
Region / City:
Global
Topic:
Radio measurement collection for Minimization of Drive Tests (MDT)
Document Type:
Technical Specification
Organization:
3rd Generation Partnership Project (3GPP)
Author:
3GPP
Target Audience:
Engineers and organizations involved in the development and implementation of radio access network technologies
Period of Effect:
Not specified
Approval Date:
Not specified
Date of Last Modification:
Not specified
Note:
Year
Theme:
Health and Social Care
Document Type:
Referral Form
Organ / Institution:
Ceredigion Social Services
Target Audience:
Healthcare professionals, Social workers
Organisation:
West Midlands Cancer Alliance
Programme:
MDT Optimisation Programme
Programme Manager:
Marie-Claire Wigley
Contact:
[email protected]
Region:
West Midlands
Sector:
Cancer care services
Focus:
Multi-Disciplinary Teams (MDTs)
Objectives:
Workforce development, leadership development, peer review reinstatement, treatment variation reduction
Key Activities:
MDT Coordinator Forum, Leadership Development Webinars, Peer Review Process
Target Audience:
Core clinical MDT members including Chairs, Deputy Chairs, Clinical Nurse Specialists, Allied Health Professionals, Radiologists, Oncologists, MDT Coordinators
Webinar Period:
June to October 2025
Follow-up Session:
Four months after October 2025
Next MDT Coordinator Forum Date:
3 July 2025
Quality Assurance Context:
Resumption of SSQD data collection and local peer review visits
Related Programme:
Specialised Services Quality Dashboard (SSQD)
Year:
Not specified
Region / City:
Not specified
Subject:
Measurement reporting for inter-RAT and E-UTRAN cells
Document type:
Technical specification
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Network engineers, technical experts
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Context description:
Technical specification detailing measurement reporting and location information for E-UTRAN and NR cells, with conformance requirements and configuration procedures.
Year:
2022
Region / city:
Online
Theme:
Configuration Updates, LTE
Document Type:
Liaison Statement
Organization / Institution:
3GPP
Author:
Man Zhang
Target Audience:
SA5
Period of validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2015
Region / City:
Rochdale, Greater Manchester, UK
Topic:
Adult Safeguarding and Risk Management
Document Type:
Protocol / Guidance
Issuing Body:
Rochdale Borough Safeguarding Adults Board
Authors:
Kaleel Khan, Jane Timson, Karen McCormick
Target Audience:
Health and social care practitioners, safeguarding professionals
Version:
29.1
Approval Date:
2 February 2015
Review Dates:
April 2015, December 2015, June 2016, June 2017, June 2018, June 2019, June 2020, November 2020, January 2021, March 2021, April 2021, June 2021, December 2021, May 2022, September 2022, December 2022, August 2023
Scope:
Multi-agency risk assessment, MDT meetings, care coordination
Key Components:
MRM Risk Action Planning, MDT meeting structure, case review templates, risk management tools, relevant legislation
Note:
Year
Year:
2026
Region / City:
India
Document Type:
Change Request
Organization / Committee:
3GPP TSG-SA5
Author:
Huawei
Work Item Code:
TEI19
Release:
Rel-19
Category:
C
Date Submitted:
2026-01-10
Meeting Number:
165
Clauses Affected:
TraceControlNrm.yaml
Related Specifications:
Other core specifications, Test specifications, O&M Specifications
Revision History:
1st Change at commit 09d56814c19dc9ad803b1dd962315a850f929df4
URL:
https://www.3gpp.org/Change-Requests
Year:
2021
Region / City:
E-meeting
Subject:
QoE and MDT alignment in NG-RAN
Document Type:
Meeting report / Technical summary
Organization:
3GPP TSG-RAN WG3
Author:
Nokia (moderator)
Intended Audience:
RAN3 members and contributors
Period Covered:
1–11 November 2021
Agenda Item:
15.4
Status:
For Approval
Key Companies Involved:
Qualcomm, Huawei, Ericsson, ZTE, Samsung, CMCC, CATT
Technical Focus:
Synchronization of MDT and QoE measurements, reporting mechanisms, network vs UE-based solutions, time-stamping alignment
Related References:
TR 38.890
Note:
Year
Subject:
Blood Borne Virus Testing, HIV, Hepatitis B, Hepatitis C
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Target Audience:
Medical Officers, nurses, midwives, students under supervision
Version:
1.5.0.0
Protocol Posting Date:
June 2024
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2025
Authors:
Gulisa Turashvili, MD, PhD; Uma G. Krishnamurti, MD, PhD; Barbara A. Crothers, DO; Giovanna A. Giannico, MD; Krisztina Hanley, MD; Anna Plotkin, MD; Anthony N. Karnezis, MD, PhD.
Note:
Accreditation Requirements
Date of Protocol Posting:
June 2024
Date of Required Use:
March 2025
Year:
2021
Region / City:
United Kingdom
Subject:
Assistance Dogs, Emergency Ambulance Services
Document Type:
Procedure
Organization / Institution:
South East Coast Ambulance Service NHS Foundation Trust
Author:
Not specified
Target Audience:
Ambulance Service Staff
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Version:
NENC v2.0
Date published:
22 January 2026
Planned review date:
October 2027
Region:
North East and North Cumbria
Healthcare system:
NHS
Clinical area:
Neurology
Condition:
Amyotrophic lateral sclerosis
Medicine:
Riluzole
Document type:
Shared care protocol
Indication:
Extension of survival or time to mechanical ventilation in ALS
Target population:
Adults
Intended audience:
NHS healthcare professionals
Initiating authority:
Neurological specialist services
Regulatory reference:
NICE Technology Appraisal TA20
Prescribing setting:
Secondary to primary care transfer
Monitoring requirements:
Liver function tests, full blood count, urea and electrolytes
Route of administration:
Oral or enteral
Licensing status:
Licensed for ALS only
Year:
2024
Region / City:
Australia
Document Type:
Regulatory submission for PBS listing
Organization:
Biogen Australia Pty Ltd
Drug Name:
Omaveloxolone (Skyclarys®)
Indication:
Friedreich’s ataxia in adults and adolescents aged 16 years and older
Dosage Form:
Capsule 50 mg, oral administration
Regulatory Status:
Orphan drug status granted by TGA, EMA and FDA approvals
Submission Date:
26 June 2024
PBAC Meeting:
March 2025
Population:
Patients aged 16 years and older with Friedreich’s ataxia
Treatment Phase:
Initial and continuing treatment
Prescriber Type:
Dental, Medical Practitioners, Nurse Practitioners, Optometrists
Restriction Type:
Authority Required (telephone/online PBS Authorities system)
Clinical Criteria:
Genetic confirmation of FXN mutation, presence of clinical symptoms, management under a specialist or consultation with specialized unit if needed
Treatment Criteria:
Must be given with best supportive care, hemodynamically stable in case of cardiac history
Administrative Advice:
Queries directed to Services Australia, prescribing information available online